Skip Ribbon Commands
Skip to main content
Translate
Donations
menu iconMenu
search iconSearch

Chemobath for Colon Cancer Evaluated at UC San Diego Moores Cancer Center

 

June 09, 2011  |  

As part of a multicenter clinical trial, surgical oncologists at UC San Diego Moores Cancer Center are comparing the effectiveness of standard chemotherapy to a tri-modality approach to halt advanced colon cancers. The objective is to determine if there is a difference in survival rates between patients who receive intravenous (IV) anti-cancer drugs or a combination of IV drugs in addition to surgery and a procedure called hyperthermic intraperitoneal chemotherapy, more commonly known as HIPEC or “chemobath.”

Soldano and Lowy

Debbie Soldano, RN, BSN, OCN and Andrew Lowy, MD

“This will be the most comprehensive study to date to examine an aggressive approach to treating colon cancers that have spread to the abdominal lining,” said Andrew Lowy, MD, chief of surgical oncology at Moores Cancer Center. “The study will also compare quality of life, cancer progression by cell subtype, toxicity levels and the reaction of the tumor cells to intervention.”

The 5-year research study, funded by the National Cancer Institute, will recruit 360 colon cancer patients. Based on significant experience with the chemobath, Moores Cancer Center was selected as one of only 10 national sites to initially enroll patients. In this randomized trial, all patients will receive the best available drugs; however, one group will also undergo surgery combined with both direct- and IV-drug delivery. When treated with chemotherapy alone, patients with peritoneal metastases have an average life expectancy of 12 to15 months.

“Colorectal cancer that has spread to the abdominal surface is extremely difficult to eradicate with surgery alone,” said Lowy. “A tiny tumor hidden in the anatomy or just a few remaining cancer cells can later spread to other areas.  We hope to show that optimal treatment must be not only immediate but multidisciplinary.”

The surgical arm of the clinical trial consists of two parts. In the first part, called cytoreductive surgery, surgeons inspect the entire abdominal cavity to remove all visible signs of malignancy. Once all suspicious growths are removed, the patient is prepared for the HIPEC or chemobath.

During the chemobath, drugs are circulated throughout the abdomen via catheters that form a circuit. The fluid containing the chemotherapy is continuously heated to 106 to107 degrees and washed over the internal organs. After 90 minutes, the solution is removed. The exposure of the tumor cell to the drug can be as much as 75-fold that which can be administered intravenously.

Traditionally, patients are administered chemotherapy by IV, but this approach is ineffective in obliterating tumors that are unattached to the bloodstream because the drug cannot reach the tumor cells. With the chemobath, the heated chemotherapy drug is poured directly into the abdomen. The combination of direct contact and heat make the tumor cells more susceptible to chemotherapy.

According to Lowy, while this approach is logical and its efficacy has been suggested by many small studies, its widespread adoption as a standard therapy requires testing in a study where patients are randomized to receive the current standard (IV chemotherapy only) or the proposed new standard (IV chemotherapy + surgery + HIPEC).

Patients who are enrolled to the IV chemotherapy arm may receive surgery and HIPEC if their disease is not responsive to their chemotherapy treatment.

Eligible patients include males and females 18 years old or older with newly diagnosed and previously untreated colon adenocarcinoma with disease limited to the peritoneal surfaces. For more information on this clinical trial, please call Debbie Soldano, RN, BSN, OCN at 858-822-6243.

# # #

Media Contact: Jackie Carr, 619-543-6163, jcarr@ucsd.edu




Media Contact

Related News

5/25/2015
Researchers at University of California, San Diego School of Medicine and Moores Cancer Center have now identified six mRNA isoforms (bits of genetic material) produced by ovarian cancer cells but not ...
5/21/2015
Using human embryonic stem cells, researchers at University of California, San Diego School of Medicine and Moores Cancer Center and Sanford-Burnham Medical Research Institute created a model that all ...
5/18/2015
A binational team from the University of California, San Diego School of Medicine and the U.S.-Mexico Border Health Commission, Mexico Section has launched a new research project aimed at promoting pr ...
5/17/2015
For parents who send their kids to dance classes to get some exercise, a new study from researchers at University of California, San Diego School of Medicine suggests most youth dance classes provide ...
5/8/2015
Therapies that specifically target mutations in a person’s cancer have been much-heralded in recent years, yet cancer cells often find a way around them. To address this, researchers at University of ...
5/7/2015
Researchers at University of California, San Diego School of Medicine and Shiley Eye Institute have identified the molecular “glue” that builds the brain connections that keep visual images clear and ...
5/7/2015
Writing in the May 7 online issue of American Journal of Geriatric Psychiatry, researchers at University of California, San Diego School of Medicine and Veterans Affairs San Diego Healthcare System su ...
5/6/2015
Each year, more than 10 million Americans seek medical attention, often in emergency situations, for symptoms of intestinal blockages. Researchers at the University California, San Diego School of Med ...


Share This Article



Follow Us